Associations - CCND1 amplification

CCND1 amplification CCND1 amplification	Melanoma Melanoma	CCND1 amplification CCND1 amplification	Melanoma Melanoma	sorafenib Sensitive: B - Late Trials	sorafenib Sensitive: B - Late Trials
CCND1 amplification CCND1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	CCND1 amplification CCND1 amplification	Estrogen Receptor Positive Breast Cancer Estrogen Receptor Positive Breast Cancer	palbociclib Resistant: C3 – Early Trials	palbociclib Resistant: C3 – Early Trials
CCND1 amplification CCND1 amplification	Solid Tumor Solid Tumor	CCND1 amplification CCND1 amplification	Solid Tumor Solid Tumor	Immunotherapy Resistant: C3 – Early Trials	Immunotherapy Resistant: C3 – Early Trials
CCND1 amplification CCND1 amplification	Breast Cancer Breast Cancer	CCND1 amplification CCND1 amplification	Breast Cancer Breast Cancer	Aromatase inhibitor Resistant: C3 – Early Trials	Aromatase inhibitor Resistant: C3 – Early Trials
CCND1 amplification CCND1 amplification	Melanoma Melanoma	CCND1 amplification CCND1 amplification	Melanoma Melanoma	ribociclib Sensitive: C3 – Early Trials	ribociclib Sensitive: C3 – Early Trials
CCND1 amplification CCND1 amplification	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	CCND1 amplification CCND1 amplification	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	palbociclib Sensitive: C3 – Early Trials	palbociclib Sensitive: C3 – Early Trials
CCND1 amplification CCND1 amplification	Melanoma Melanoma	CCND1 amplification CCND1 amplification	Melanoma Melanoma	toripalimab Resistant: C3 – Early Trials	toripalimab Resistant: C3 – Early Trials
CCND1 amplification CCND1 amplification	Head and Neck Cancer Head and Neck Cancer	CCND1 amplification CCND1 amplification	Head and Neck Cancer Head and Neck Cancer	cetuximab + palbociclib Sensitive: C3 – Early Trials	cetuximab + palbociclib Sensitive: C3 – Early Trials
CCND1 amplification CCND1 amplification	Breast Cancer Breast Cancer	CCND1 amplification CCND1 amplification	Breast Cancer Breast Cancer	lapatinib Sensitive: D – Preclinical	lapatinib Sensitive: D – Preclinical